United Therapeutics officer proposes $4.52M share sale
The proposed shares are attributed to a cash-paid stock option exercise from the issuer on October 15, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Paul Mahon, identified as an officer of United Therapeutics Corp, gave notice of a proposed sale of 8,300 common shares on October 15, 2026. The proposed sale has an aggregate market value of $4,517,709.09, and Morgan Stanley Smith Barney LLC is named as broker. The shares are listed as acquired from the issuer through a stock option exercise on October 15, 2026, with cash payment. The notice also lists six sales during the preceding three months, each involving 8,300 shares.
Key Figures
Key Terms
Rule 144 regulatory
Stock Option Exercise financial
Securities To Be Sold regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.